Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial

被引：26

作者：

Amerikanou, Charalampia ^{[1
]}

Kanoni, Stavroula ^{[2
]}

Kaliora, Andriana C. ^{[1
]}

Barone, Angela ^{[3
]}

Bjelan, Mladen ^{[4
]}

D'Auria, Giuseppe ^{[5
,6
]}

Gioxari, Aristea ^{[1
]}

Gosalbes, Maria Jose ^{[6
,7
,8
]}

Mouchti, Sofia ^{[3
]}

Stathopoulou, Maria G. ^{[9
]}

Soriano, Beatriz ^{[10
]}

Stojanoski, Stefan ^{[4
,11
]}

Banerjee, Rajarshi ^{[3
]}

Halabalaki, Maria ^{[12
]}

Mikropoulou, Eleni V. ^{[12
]}

Kannt, Aimo ^{[13
,14
,15
]}

Lamont, John ^{[16
]}

Llorens, Carlos ^{[10
]}

Marascio, Fernando ^{[17
]}

Marascio, Miriam ^{[17
]}

Roig, Francisco J. ^{[10
,18
]}

Smyrnioudis, Ilias ^{[19
]}

Varlamis, Iraklis ^{[20
]}

Visvikis-Siest, Sophie ^{[9
]}

Vukic, Milan ^{[21
]}

Milic, Natasa ^{[4
]}

Medic-Stojanoska, Milica ^{[4
,22
]}

Cesarini, Lucia ^{[23
]}

Campolo, Jonica ^{[24
]}

Gastaldelli, Amalia ^{[25
]}

Deloukas, Panos ^{[2
,26
]}

Trivella, Maria Giovanna ^{[24
,25
]}

Francino, M. Pilar ^{[6
,7
,8
]}

Dedoussis, George V. ^{[1
]}

机构：

[1] Harokopio Univ, Sch Hlth Sci & Educ, Dept Nutr & Dietet, Athens, Greece

[2] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London EC1M 6BQ, England

[3] Perspectum Ltd, Oxford, England

[4] Univ Novi Sad, Fac Med, Novi Sad, Serbia

[5] Fundacio Foment Invest Sanitaria & Biomed Comnita, Sequencing & Bioinformat Serv, Comunitat Valenciana FISABIO Salut Publ, Avda Catalunya 21, Valencia 46020, Spain

[6] CIBER Epidmiol & Salud Publ, Av Monforte Lemos 3-5, Madrid 28029, Spain

[7] Univ Valencia, Joint Res Unit Genom & Hlth Fundacio Foment Inves, CSIC, Avda Catalunya 21, Valencia 46020, Spain

[8] Univ Valencia, Inst Biol Integrat Sistemes, Avda Catalunya 21, Valencia 46020, Spain

[9] Univ Loraine, UMR INSERM U1122, PCV, IGE, Nancy, France

[10] Univ Valencia, Biotechvana, Parc Cient, Valencia, Spain

[11] Oncol Inst Vojvodina, Ctr Imaging Diagnost, Sremska Kamenica, Serbia

[12] Natl & Kapodistrian Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, Athens, Greece

[13] Sanofi Res & Dev, Ind Pk Hoechst, D-65926 Frankfurt, Germany

[14] Goethe Univ Frankfurt, Inst Clin Pharmacol, D-60590 Frankfurt, Germany

[15] Fraunhofer Inst Translat Med & Pharmacol ITMP, D-60596 Frankfurt, Germany

[16] Randox Labs Ltd, Co Antrim, Northern Irelan, England

[17] Marascio Fernando, Intervideo, I-88100 Catanzaro, CZ, Italy

[18] Univ San Jorge, Fac Ciencias Salud, Zaragoza 50830, Spain

[19] Chios Mast Gum Growers Assoc, Chios, Greece

[20] Harokopio Univ, Dept Informat & Telemat, Athens, Greece

[21] Univ East Sarajevo, Fac Technol Zvornik, Dept Food Technol, Zvornik 75400, Bosnia & Herceg

[22] Clin Ctr Vojvodina, Clin Endocrinol Diabet & Metab Dis, Novi Sad, Serbia

[23] Niguarda Ca Grande Hosp Milan, Div Hepatol & Gastroenterol, Milan, Italy

[24] CNR, Inst Clin Physiol, Milan, Italy

[25] CNR, Inst Clin Physiol, Cardiometabol Risk Unit, Pisa, Italy

[26] Queen Mary Univ London, Ctr Genom Hlth, Life Sci, London, England

来源：

MOLECULAR NUTRITION & FOOD RESEARCH | 2021年 / 65卷 / 10期

关键词：

Mastiha; metabolomics; microbiota dysbiosis; MRI; NAFLD; NASH; MULTIPARAMETRIC MAGNETIC-RESONANCE; FATTY LIVER-DISEASE; GUT MICROBIOTA; FIBROSIS; DATABASE; GLUCOSE; IMMUNE; SCORE;

D O I：

10.1002/mnfr.202001178

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Scope Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with poor therapeutic strategies. Mastiha possesses antioxidant/anti-inflammatory and lipid-lowering properties. The authors investigate the effectiveness of Mastiha as a nonpharmacological intervention in NAFLD. Methods and Results Ninety-eight patients with NAFLD in three countries (Greece, Italy, Serbia) are randomly allocated to either Mastiha or Placebo for 6 months, as part of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The authors assess NAFLD severity via magnetic resonance imaging (MRI) scanning and LiverMultiScan technique and evaluate the effectiveness of Mastiha through medical, anthropometric, biochemical, metabolomic, and microbiota assessment. Mastiha is not superior to Placebo on changes in iron-corrected T1 (cT1) and Liver Inflammation Fibrosis score (LIF) in entire patient population; however, after BMI stratification (BMI <= 35 kg m(-2) and BMI > 35 kg m(-2)), severely obese patients show an improvement in cT1 and LIF in Mastiha versus Placebo. Mastiha increases dissimilarity of gut microbiota, as shown by the Bray-Curtis index, downregulates Flavonifractor, a known inflammatory taxon and decreases Lysophosphatidylcholines-(LysoPC) 18:1, Lysophosphatidylethanolamines-(LysoPE) 18:1, and cholic acid compared to Placebo. Conclusion Mastiha supplementation improves microbiota dysbiosis and lipid metabolite levels in patients with NAFLD, although it reduces parameters of liver inflammation/fibrosis only in severely obese patients.

引用

页数：10

共 46 条

[11]

EASL, 2016, OBESITY FACTS, V9, P65, DOI [10.1159/000443344, 10.1016/j.jhep.2015.11.004, 10.1007/s00125-016-3902-y]

[12] Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease [J].

Eddowes, P. J. ;

McDonald, N. ;

Davies, N. ;

Semple, S. I. K. ;

Kendall, T. J. ;

Hodson, J. ;

Newsome, P. N. ;

Flintham, R. B. ;

Wesolowski, R. ;

Blake, L. ;

Duarte, R. V. ;

Kelly, C. J. ;

Herlihy, A. H. ;

Kelly, M. D. ;

Olliff, S. P. ;

Hubscher, S. G. ;

Fallowfield, J. A. ;

Hirschfield, G. M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (05) :631-644

[13] A New Measure of the Effective Number of Tests, a Practical Tool for Comparing Families of Non-Independent Significance Tests [J].

Galwey, Nicholas W. .

GENETIC EPIDEMIOLOGY, 2009, 33 (07) :559-568

[14] Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J].

Harrison, Stephen A. ;

Bashir, Mustafa R. ;

Guy, Cynthia D. ;

Zhou, Rong ;

Moylan, Cynthia A. ;

Frias, Juan P. ;

Alkhouri, Naim ;

Bansal, Meena B. ;

Baum, Seth ;

Neuschwander-Tetri, Brent A. ;

Taub, Rebecca ;

Moussa, Sam E. .

LANCET, 2019, 394 (10213) :2012-2024

[15] NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis [J].

Harrison, Stephen A. ;

Rossi, Stephen J. ;

Paredes, Angelo H. ;

Trotter, James F. ;

Bashir, Mustafa R. ;

Guy, Cynthia D. ;

Banerjee, Rajarshi ;

Jaros, Mark J. ;

Owers, Sandra ;

Baxter, Bryan A. ;

Ling, Lei ;

DePaoli, Alex M. .

HEPATOLOGY, 2020, 71 (04) :1198-1212

[16] Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics [J].

He, Xuyun ;

Ji, Guang ;

Jia, Wei ;

Li, Houkai .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (03)

[17] A population-based study on the prevalence of NASH using scores validated against liver histology [J].

Hyysalo, Jenni ;

Mannisto, Ville T. ;

Zhou, You ;

Arola, Johanna ;

Karja, Vesa ;

Leivonen, Marja ;

Juuti, Anne ;

Jaser, Nabil ;

Lallukka, Susanna ;

Kakela, Pirjo ;

Venesmaa, Sari ;

Simonen, Marko ;

Saltevo, Juha ;

Moilanen, Leena ;

Korpi-Hyovalti, Eeva ;

Keinanen-Kiukaanniemi, Sirkka ;

Oksa, Heikki ;

Orho-Melander, Marju ;

Valenti, Luca ;

Fargion, Silvia ;

Pihlajamaki, Jussi ;

Peltonen, Markku ;

Yki-Jarvinen, Hannele .

JOURNAL OF HEPATOLOGY, 2014, 60 (04) :839-846

[18] Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease [J].

Jayaswal, Arjun N. A. ;

Levick, Christina ;

Selvaraj, Emmanuel A. ;

Dennis, Andrea ;

Booth, Jonathan C. ;

Collier, Jane ;

Cobbold, Jeremy ;

Tunnicliffe, Elizabeth M. ;

Kelly, Matthew ;

Barnes, Eleanor ;

Neubauer, Stefan ;

Banerjee, Rajarshi ;

Pavlides, Michael .

LIVER INTERNATIONAL, 2020, 40 (12) :3071-3082

[19] Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease [J].

Jiang, Weiwei ;

Wu, Na ;

Wang, Xuemei ;

Chi, Yujing ;

Zhang, Yuanyuan ;

Qiu, Xinyun ;

Hu, Ying ;

Li, Jing ;

Liu, Yulan .

SCIENTIFIC REPORTS, 2015, 5

[20] Plasma metabolomic profile in nonalcoholic fatty liver disease [J].

Kalhan, Satish C. ;

Guo, Lining ;

Edmison, John ;

Dasarathy, Srinivasan ;

McCullough, Arthur J. ;

Hanson, Richard W. ;

Milburn, Mike .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (03) :404-413

← 1 2 3 4 5 →